- Home
- HIX vs RLMD Comparison
HIX vs RLMD Comparison
Compare HIX & RLMD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | HIX | RLMD |
|---|---|---|
| Founded | 1998 | 2004 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance/Investors Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 376.5M | 319.7M |
| IPO Year | 1998 | 2012 |
Fundamental Metrics
Financial Performance| Metric | HIX | RLMD |
|---|---|---|
| Price | $3.90 | $6.01 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $12.40 |
| AVG Volume (30 Days) | 318.2K | ★ 1.6M |
| Earning Date | 01-01-0001 | 03-19-2026 |
| Dividend Yield | ★ 13.14% | N/A |
| EPS Growth | N/A | ★ 45.28 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $13,070.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 154.83 |
| 52 Week Low | $3.65 | $0.24 |
| 52 Week High | $4.39 | $7.41 |
Technical Indicators
Market Signals| Indicator | HIX | RLMD |
|---|---|---|
| Relative Strength Index (RSI) | 33.35 | 58.11 |
| Support Level | $3.88 | $3.74 |
| Resistance Level | $4.26 | $7.41 |
| Average True Range (ATR) | 0.06 | 0.55 |
| MACD | -0.01 | -0.03 |
| Stochastic Oscillator | 5.77 | 56.61 |
Price Performance
Historical ComparisonAbout HIX Western Asset High Income Fund II Inc.
Western Asset High Income Fund II Inc is a diversified closed-end management investment company. Its investment objective is to maximize current income by investing at least 80% of its net assets and borrowings for investment purposes in high-yield debt securities.
About RLMD Relmada Therapeutics Inc.
Relmada Therapeutics Inc is a clinical-stage biotechnology company. It is engaged in developing chemical entities with novel versions of drug products that address areas of high unmet medical need in the treatment of central nervous system diseases. The company is focused on the development of esmethadone (d-methadone, dextromethadone, REL-1017), an N-methyl-D-aspartate (NMDA) receptor antagonist. Its key product candidate, esmethadone, is an oral agent for the treatment of depression and other potential indications.